Imatinib-d4 (STI571-d4) is a deuterium-labeled version of Imatinib (STI571), an orally bioavailable tyrosine kinase inhibitor. It selectively targets and inhibits the activity of BCR/ABL, v-Abl, PDGFR, and c-kit kinases, and is intended for research use only. This compound serves as a tracer and an internal standard for quantitative analysis, leveraging stable heavy isotopes like deuterium to potentially influence pharmacokinetic and metabolic profiles of drugs.
- Can be used as a tracer
- Can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS
- Stable heavy isotopes of hydrogen, carbon, and other elements incorporated into drug molecules largely serve as tracers for quantitation during drug development
- Deuteration can affect pharmacokinetic and metabolic profiles of drugs